Welcome to our dedicated page for Cryoport news (Ticker: CYRX), a resource for investors and traders seeking the latest updates and insights on Cryoport stock.
Cryoport, Inc. reports developments in temperature-controlled supply chain solutions for the life sciences, with recurring updates tied to regenerative medicine and cell and gene therapy support. Its platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services and cryogenic systems.
Company news commonly covers quarterly and annual operating results, revenue guidance, clinical-trial and commercial therapy support, Life Sciences Services and Life Sciences Products activity, MVE Biological Solutions cryogenic systems, product introductions such as Fusion freezers, and quality or regulatory certifications for therapeutic-cell transport.
Cryoport (NASDAQ: CYRX) has announced the opening of a new 55,000-square-foot Global Supply Chain Center (GSCC) in Louvres, France, near Paris Charles de Gaulle Airport. The facility represents the company's third global supply chain center campus, strengthening its temperature-controlled supply chain solutions network.
The Paris GSCC will provide 24-hour worldwide dispatch capabilities and immediate logistics support for biopharma, including cell and gene therapies, biologics, animal health, and reproductive medicine. Future phases will incorporate BioServices, biostorage, QP drug management, and Importer of Record services. The facility's development was partially funded by a grant from the Île-de-France region, with an official grand opening scheduled for November 20, 2025.
Cryoport (NASDAQ: CYRX) reported strong Q2 2025 financial results with total revenue increasing 14% year-over-year to $45.5 million. The company's Commercial Cell & Gene Therapy revenue grew 33% to $8.7 million, while Life Sciences Services revenue rose 21%, including a 28% increase in BioStorage/BioServices revenue.
Key highlights include the completion of a strategic partnership with DHL Group and the divestiture of CRYOPDP, resulting in a significant capital infusion. The company supports 728 global clinical trials, including 82 in Phase 3. Cryoport maintained its full-year 2025 revenue guidance of $165-172 million and reported $426 million in cash and equivalents as of June 30, 2025.
Cryoport (NASDAQ:CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences, has scheduled its Q2 2025 earnings release for August 5, 2025 after U.S. markets close.
The company will release a document titled "Cryoport Second Quarter 2025 in Review" at 4:05 p.m. ET, followed by a Q&A conference call at 5:00 p.m. ET. Management will address questions from the investment community regarding the reported results, accompanied by a slide deck presentation.
The earnings call can be accessed via phone (U.S.: 1-800-717-1738, International: 1-646-307-1865) or webcast through the company's investor relations website. A replay will be available until August 12, 2025.
Cryoport (NASDAQ:CYRX) has announced the launch of its next-generation vapor shippers, the SC 4/2V and SC 4/3V, through its MVE Biological Solutions division. The new models feature significant improvements in hold times, with the SC 4/2V extending from 13 to 19 days and the SC 4/3V from 21 to 26 days.
The enhanced vapor shippers incorporate several innovative features, including the patented BEND DON'T BREAK™ technology for impact absorption, an integrated lid locking tab, and patent-pending Vapor Shield Technology to prevent vacuum loss. These improvements are designed to provide better protection for sensitive biological materials during transportation, including cells, tissues, vaccines, and reproductive health materials.
Cryoport (NASDAQ: CYRX) reported Q1 2025 revenue of $41.0 million from continuing operations, up 10% year-over-year. The company's commercial Cell & Gene therapy revenue grew 33%, while Life Sciences Services revenue increased 17%. As of March 31, 2025, Cryoport supported 711 global clinical trials, including 79 in Phase 3. The company announced a strategic partnership with DHL, including the planned divestiture of CRYOPDP expected to close in Q2/Q3 2025.
Financial highlights include a gross margin of 45.4%, operating costs reduction of 13.7%, and a net loss of $12.0 million ($0.28 per share). The company maintains $244.0 million in cash and investments. For fiscal 2025, Cryoport reiterates revenue guidance of $165.0-172.0 million, representing 5-10% growth.
Cryoport (CYRX), a global life sciences supply chain solutions provider, has scheduled its first quarter 2025 financial results announcement for May 7, 2025 after U.S. markets close. The company will release its earnings report alongside a comprehensive document titled 'Cryoport First Quarter 2025 in Review' at 4:05 p.m. ET, providing detailed financial and operational performance updates.
Management will host a Q&A conference call at 5:00 p.m. ET the same day, accompanied by a slide deck presentation. The call will be accessible via U.S. dial-in (1-800-717-1738) and International dial-in (1-646-307-1865) using Conference ID: 1180684. A webcast replay will be available until May 14, 2025.
DHL Group has announced the acquisition of CRYOPDP from Cryoport, Inc. (NASDAQ: CYRX), marking a significant expansion in specialized pharma logistics. CRYOPDP, operating in 15 countries and handling over 600,000 shipments annually across 135 countries, specializes in clinical trials, biopharma, and cell & gene therapy logistics.
The acquisition strengthens DHL's Life Sciences and Healthcare business, which generated over EUR 5 billion in global revenue in 2024. As part of the deal, DHL and Cryoport will form a strategic partnership to enhance their supply chain service offerings in the global life sciences sector.
This strategic move aligns with DHL Group's Strategy 2030, focusing on temperature-controlled networks and specialty courier coverage. The partnership aims to leverage DHL's global logistics capabilities with Cryoport's specialized solutions, particularly expanding their reach in APAC and EMEA regions.
Cryoport (Nasdaq: CYRX), a leading global supply chain solutions provider for the life sciences industry, has announced an investor call scheduled for March 31, 2025, at 8:30 a.m. ET. The call will focus on discussing the company's recent strategic partnership with DHL Group and DHL's acquisition of CRYOPDP.
The conference call will feature management team presentations followed by a Q&A session addressing investor inquiries about these developments. A slide deck will accompany the presentation.
The recorded call will be available approximately three hours after completion in the Investor Relations section at www.cryoportinc.com. A dial-in replay will be accessible until April 7, 2025, via:
- United States: 1-844-512-2921
- International: 1-412-317-6671
- Replay entry code: 1197941#
Cryoport (NASDAQ: CYRX) has announced the launch of MVE Biological Solutions' High-Efficiency 800 C (HE 800 C), a new cryogenic freezer designed for fertility clinics, biorepositories, and clinical laboratories. The device offers ultra-cold storage at -190°C with a capacity to store over 22,000 ½cc straws in a compact, space-efficient design.
The HE 800 C features compatibility with SUC-1 inventory management systems for streamlined sample organization and retrieval. The freezer combines ergonomic features for easier sample handling, reducing strain on laboratory personnel while maintaining consistent performance in preserving sensitive biological materials.